{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:03:09Z","timestamp":1788825789132,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01493-0","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:47:40Z","timestamp":1753436860000},"page":"2853-2864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Effectiveness and Safety of Risankizumab in Psoriasis: A Comprehensive Analysis from the Saudi Arabia Psoriasis Registry (PSORSA)"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-0595","authenticated-orcid":false,"given":"Mohammed Ibrahim","family":"Fatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7663-5115","authenticated-orcid":false,"given":"Abdulaziz","family":"Madani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3869-148X","authenticated-orcid":false,"given":"Fahad","family":"Alzuriqan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1282-1256","authenticated-orcid":false,"given":"Abdullah","family":"Albadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-9086","authenticated-orcid":false,"given":"Ahmed","family":"Aljedai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-6193","authenticated-orcid":false,"given":"Hajer","family":"Almudaiheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-6143","authenticated-orcid":false,"given":"Maysa Tariq","family":"Eshmawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"8","key":"1493_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015354","volume":"4","author":"P Di Meglio","year":"2014","unstructured":"Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8): a015354.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3 Pt 1","key":"1493_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"1493_CR3","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.3390\/ijms21197041","volume":"21","author":"YR Woo","year":"2020","unstructured":"Woo YR, Park CJ, Kang H, Kim JE. The risk of systemic diseases in those with psoriasis and psoriatic arthritis: from mechanisms to clinic. Int J Mol Sci. 2020;21(19):7041.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"1493_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"4","key":"1493_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/1346-8138.17132","volume":"51","author":"M Tokuyama","year":"2024","unstructured":"Tokuyama M, Fan P, Wang G, Choe YB, Song HJ, Tsai D, Sindhvananda J, Mabuchi T, Ozawa A, Investigative Team of the Asian Society for Psoriasis. Epidemiological analysis of the patients with psoriasis in Asian countries and region using the same clinical case cards between 2020 and 2022. J Dermatol. 2024;51(4):567\u201383.","journal-title":"J Dermatol"},{"issue":"7","key":"1493_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jama.2009.1092","volume":"302","author":"NA Dreyer","year":"2009","unstructured":"Dreyer NA, Garner S. Registries for robust evidence. JAMA. 2009;302(7):790\u20131. https:\/\/doi.org\/10.1001\/jama.2009.1092.","journal-title":"JAMA"},{"issue":"3","key":"1493_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/09546634.2018.1506084","volume":"30","author":"M Amin","year":"2019","unstructured":"Amin M, Lee EB, Bhutani T, Wu JJ. Review of European registries for psoriasis. J Dermatolog Treat. 2019;30(3):227\u201336.","journal-title":"J Dermatolog Treat"},{"key":"1493_CR8","doi-asserted-by":"crossref","unstructured":"Gliklich RE, Leavy MB, Dreyer NA, editors. Registries for evaluating patient outcomes: a user\u2019s guide. 4th edition. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Sep. Chapter 1, Patient Registries.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562581\/","DOI":"10.23970\/AHRQEPCREGISTRIES4"},{"issue":"4","key":"1493_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaad.2016.03.020","volume":"75","author":"G DiMarco","year":"2016","unstructured":"DiMarco G, Hill D, Feldman SR. Review of patient registries in dermatology. J Am Acad Dermatol. 2016;75(4):824\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.020. (Epub 2016 Apr 16).","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1493_CR10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1177\/12034754231191509","volume":"27","author":"MJ Gooderham","year":"2023","unstructured":"Gooderham MJ, Bissonnette R, Kalia S, Papp KA, Guenther LC, Gulliver WP, Ho V, Shear NH, Vender R, Gniadecki R, Prajapati VH, Turchin I, Langholff W, Parnell K, Simpson SD, Abbarin N, Lakhani O, Alhusayen R. Baseline characteristics of Canadian patients in the psoriasis longitudinal assessment and registry (PSOLAR). J Cutan Med Surg. 2023;27(6):594\u2013600. https:\/\/doi.org\/10.1177\/12034754231191509. (Epub 2023 Aug 11).","journal-title":"J Cutan Med Surg"},{"key":"1493_CR11","unstructured":"The Jamovi Project. Jamovi version 2.4 [Computer Software]. 2023. Retrieved from https:\/\/www.jamovi.org"},{"key":"1493_CR12","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2023. Retrieved from https:\/\/www.R-project.org\/"},{"key":"1493_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40257-017-0274-0","volume":"18","author":"D H\u00e4gg","year":"2017","unstructured":"H\u00e4gg D, Sundstr\u00f6m A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure psoriasis area and severity index (PASI) in 5438 Swedish register patients. Am J Clin Dermatol. 2017;18:583\u201390.","journal-title":"Am J Clin Dermatol"},{"issue":"5 Suppl 93","key":"1493_CR14","first-page":"S14","volume":"33","author":"V Oji","year":"2015","unstructured":"Oji V, Luger TA. The skin in psoriasis: assessment and challenges. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S14\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"1493_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.adengl.2017.10.003","volume":"108","author":"M Llamas-Velasco","year":"2017","unstructured":"Llamas-Velasco M, De la Cueva P, Notario J, Mart\u00ednez-Pilar L, Martorell A, Moreno-Ram\u00edrez D. Moderate psoriasis: a proposed definition. Actas Dermo-Sifiliogr\u00e1ficas (English Edition). 2017;108(10):911\u20137.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"issue":"3","key":"1493_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"PL Mattei","year":"2014","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1493_CR17","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s10067-020-05444-2","volume":"40","author":"A Al-Herz","year":"2021","unstructured":"Al-Herz A, Saleh K, Al-Awadhi A, Al-Kandari W, Hasan E, Ghanem A, Hussain M, Ali Y, Nahar E, Alenizi A, Hayat S, Abutiban F, Aldei A, Alhajeri H, Alhadhood N, Bahbahani H, Tarakmeh H, Mokaddem K, Khadrawy A, Fazal A, Zaman A, Mazloum G, Bartella Y, Hamed S, Alsouk R, Al-Saber A, Kuwait Registry for Rheumatic Diseases (KRRD). Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait. Clin Rheumatol. 2021;40(5):1759\u201365. https:\/\/doi.org\/10.1007\/s10067-020-05444-2. (Epub 2020 Oct 12).","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1493_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2174\/1573397112666160728100812","volume":"12","author":"Y El Miedany","year":"2016","unstructured":"El Miedany Y, El Gaafary M, Youssef S, Almedany S, Palmer D. Using simulation in clinical education: psoriasis area and severity index (PASI) score assessment. Curr Rheumatol Rev. 2016;12(3):195\u2013201.","journal-title":"Curr Rheumatol Rev"},{"issue":"3","key":"1493_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13555-022-00690-5","volume":"12","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Gooderham M, Griffiths CEM, Armstrong AW, Zhu B, Burge R, Gallo G, Guo J, Garrelts A, Lebwohl M. Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1 year: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(3):727\u201340. https:\/\/doi.org\/10.1007\/s13555-022-00690-5. (Epub 2022 Feb 23).","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1493_CR20","first-page":"1","volume":"4","author":"D Tha\u00e7i","year":"2025","unstructured":"Tha\u00e7i D, Ohtsuki M, Maul JT, Szegedi A, Luna PC, Lynde CW, Soliman AM, Wang H, Kaufmann C, Ashley DG, Madihlaba T. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis: interim analysis from the VALUE global prospective post-marketing observational study at 25 months. Dermatol Ther. 2025;4:1\u20134.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1493_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ad.2024.02.030","volume":"116","author":"A Martorell-Calatayud","year":"2025","unstructured":"Martorell-Calatayud A, Santos-Alarc\u00f3n S, Sahuquillo-Torralba A, Rivera-D\u00edaz R, Belinch\u00f3n-Romero I, Ruiz-Genao D, Romero-Mat\u00e9 A, Ruiz-Villaverde R, Ferran-Farr\u00e9s M, Gallardo-Hern\u00e1ndez F, Almenara-Blasco M. Real-world safety and efficacy of risankizumab in psoriatic patients: a multicenter, retrospective, and not-interventional study. Actas dermo-sifiliograficas. 2025;116(2):125\u201333.","journal-title":"Actas dermo-sifiliograficas"},{"issue":"Supplement_1","key":"1493_CR22","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/ecco-jcc\/jjae190.0896","volume":"19","author":"L Peyrin-Biroulet","year":"2025","unstructured":"Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, Platt A, Joshi N, Cross RK. P0722 Efficacy and safety of risankizumab in patients with moderate to severe Crohn\u2019s disease: results from the one-year SEQUENCE open-label long-term extension. J Crohn\u2019s Colitis. 2025;19(Supplement_1):1405\u20137.","journal-title":"J Crohn\u2019s Colitis."},{"issue":"4","key":"1493_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Daud\u00e9n E, Conrad C, Mendes-Bastos P, Ferreira P, Leite L, Lu JD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas-Velasco M, Del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung J, Nogueira M, Chiricozzi A. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567\u201379. https:\/\/doi.org\/10.1007\/s40257-021-00598-4. (Epub 2021 Mar 30).","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1493_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/jamadermatol.2022.3171","volume":"158","author":"ML Nielsen","year":"2022","unstructured":"Nielsen ML, Petersen TC, Maul JT, Wu JJ, Rasmussen MK, Bertelsen T, Ajgeiy KK, Skov L, Thomsen SF, Thyssen JP, Egeberg A. Multivariable predictive models to identify the optimal biologic therapy for treatment of patients with psoriasis at the individual level. JAMA Dermatol. 2022;158(10):1149\u201356.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1493_CR25","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/jcm12093233","volume":"12","author":"M Megna","year":"2023","unstructured":"Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9):3233.","journal-title":"J Clin Med"},{"issue":"1","key":"1493_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12962-023-00504-1","volume":"21","author":"Y AlRuthia","year":"2023","unstructured":"AlRuthia Y, Alfakhri AH, Alharbi I, Alghamdi FA, Alanazi MA, Alrabiah AA, Alsouan AA, Alshaikh AA, Almasaoud MA. Comparative effectiveness and cost evaluation of risankizumab and adalimumab in the management of psoriasis: a real-world study in Saudi Arabia. Cost Eff Resour Alloc. 2023;21(1):95. https:\/\/doi.org\/10.1186\/s12962-023-00504-1.","journal-title":"Cost Eff Resour Alloc"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01493-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01493-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01493-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:05:39Z","timestamp":1758719139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01493-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01493-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no potential conflicts of interest or competing interests to disclose. Mohammed Ibrahim Fatani has nothing to disclose. Abdulaziz Madani has nothing to disclose. Fahad Alzuriqan has nothing to disclose. Abdullah Albadri has nothing to disclose. Ahmed Aljedai has nothing to disclose. Hajer Almudaiheem has nothing to disclose. Maysa Tariq Eshmawi has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The research was conducted following the ethical principles set out in the Declaration of Helsinki and approved by the institutional review board (IRB) of the Saudi Ministry of Health (IRB Log No: 25-1M). Due to the retrospective nature of the study, informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}